Segall Bryant & Hamill LLC Boosts Stock Position in Krystal Biotech, Inc. (NASDAQ:KRYS)

Segall Bryant & Hamill LLC lifted its holdings in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 352.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 157,144 shares of the company’s stock after buying an additional 122,407 shares during the quarter. Segall Bryant & Hamill LLC owned approximately 0.55% of Krystal Biotech worth $28,605,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. EFG Asset Management North America Corp. lifted its position in shares of Krystal Biotech by 0.5% in the second quarter. EFG Asset Management North America Corp. now owns 12,555 shares of the company’s stock valued at $2,308,000 after acquiring an additional 60 shares in the last quarter. GAMMA Investing LLC boosted its stake in Krystal Biotech by 160.3% during the 2nd quarter. GAMMA Investing LLC now owns 151 shares of the company’s stock worth $28,000 after purchasing an additional 93 shares during the last quarter. Nisa Investment Advisors LLC raised its position in shares of Krystal Biotech by 11.1% in the second quarter. Nisa Investment Advisors LLC now owns 940 shares of the company’s stock valued at $173,000 after buying an additional 94 shares during the last quarter. Arizona State Retirement System raised its position in shares of Krystal Biotech by 2.1% in the second quarter. Arizona State Retirement System now owns 5,147 shares of the company’s stock valued at $945,000 after buying an additional 108 shares during the last quarter. Finally, Fiera Capital Corp lifted its stake in shares of Krystal Biotech by 0.8% in the second quarter. Fiera Capital Corp now owns 16,208 shares of the company’s stock worth $2,976,000 after buying an additional 130 shares in the last quarter. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Insiders Place Their Bets

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $197.76, for a total value of $4,944,000.00. Following the completion of the transaction, the insider now owns 1,500,882 shares in the company, valued at approximately $296,814,424.32. This represents a 1.64 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 14.10% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of equities research analysts have commented on KRYS shares. Citigroup lifted their target price on Krystal Biotech from $204.00 to $206.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. Evercore ISI upped their target price on shares of Krystal Biotech from $201.00 to $206.00 and gave the company an “outperform” rating in a research report on Monday, August 12th. William Blair upgraded shares of Krystal Biotech to a “strong-buy” rating in a research report on Friday, August 30th. Chardan Capital boosted their price target on shares of Krystal Biotech from $153.00 to $208.00 and gave the company a “buy” rating in a research note on Monday, August 5th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $221.00 price objective on shares of Krystal Biotech in a research report on Tuesday, November 5th. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Krystal Biotech presently has an average rating of “Buy” and an average target price of $197.00.

Krystal Biotech Stock Performance

Krystal Biotech stock opened at $177.85 on Wednesday. The firm has a market capitalization of $5.11 billion, a PE ratio of 100.48 and a beta of 0.82. Krystal Biotech, Inc. has a one year low of $99.00 and a one year high of $219.34. The stock’s 50 day moving average price is $180.59 and its 200 day moving average price is $181.90.

Krystal Biotech (NASDAQ:KRYS) last announced its earnings results on Monday, November 4th. The company reported $0.91 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.84 by $0.07. The business had revenue of $83.84 million for the quarter, compared to analyst estimates of $82.94 million. Krystal Biotech had a return on equity of 7.54% and a net margin of 21.68%. The company’s revenue for the quarter was up 879.9% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.67) earnings per share. On average, analysts forecast that Krystal Biotech, Inc. will post 2.97 earnings per share for the current fiscal year.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).